RT Journal Article
SR Electronic
T1 Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19009712
DO 10.1101/19009712
A1 Gu, Shengqing
A1 Lheureux, Stephanie
A1 Sayad, Azin
A1 Cybulska, Paulina
A1 Hogen, Liat Ben-David
A1 Vyarvelska, Iryna
A1 Tu, Dongsheng
A1 Parulekar, Wendy
A1 Nankivell, Matthew
A1 Kehoe, Sean
A1 Chi, Dennis
A1 Levine, Douglas A.
A1 Bernardini, Marcus Q.
A1 Rosen, Barry
A1 Oza, Amit
A1 Neel, Benjamin G.
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/19009712.abstract
AB High-grade serous tubo-ovarian carcinoma (HGSC) is a major cause of cancer-related death. Whether treatment order—primary debulking surgery followed by adjuvant chemotherapy (PDS) or neo-adjuvant chemotherapy with interval surgery (NACT)—affects outcome is controversial. We developed a mathematical framework that holds for hierarchical or stochastic models of tumor initiation and reproduces HGSC clinical course. After estimating parameter values, we infer that most patients harbor chemo-resistant HGSC cells at diagnosis, and that if complete debulking (<1 mm residual tumor) can be achieved, PDS is superior to NACT due to better depletion of resistant cells. We further predict that earlier diagnosis of primary HGSC, followed by complete debulking, could improve survival, but its benefit in relapsed patients is likely to be limited. Our predictions are supported by primary clinical data from multiple cohorts. Our results have clear implications for these key issues in HGSC management.Significance Statement The optimal order and timing of surgery and chemotherapy, and the potential benefits of earlier diagnosis of HGSC, remain controversial. We developed a mathematical framework of tumor dynamics to address such issues, populated the model with primary clinical data and reliably recapitulated clinical observations. Our model prospectively predicts that: (1) PDS is superior to NACT when complete debulking is feasible; (2) timely adjuvant chemotherapy is critical for the outcome of PDS with <1mm, but not >1mm, residual tumors; (3) earlier detection of relapse is unlikely to be beneficial with current therapies; (4) earlier detection of primary HGSC, followed by complete debulking, could have substantial benefit. Our model provides insights into the evolutionary dynamics of HGSC, argues for new clinical trials to optimize HGSC therapy, and is potentially applicable to other tumor types.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Terry Fox Foundation (TFPPG 020003), National Cancer Institute (R37 49152), and Department of Defense (60167542 104703 A) (to B.G.N.), and a DCA Award from University of Toronto (to S.G.).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll data were acquired from published clinical trials or retrospective studies.